Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists probe Gut-Liver link in alcohol and fatty liver cancers

NCT ID NCT03307408

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 180 people with liver cancer (hepatocellular carcinoma) who also had cirrhosis caused by either fatty liver disease or alcohol use. Researchers compared immune cells and gut bacteria in the liver to understand why cancer develops. The goal was to gather knowledge, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

180 people

The number who actually took part.

Started

Feb 2017

Finished

Sep 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with alcoholic or non-alcoholic fatty liver diseases.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Group 1 Inclusion Criteria : * Available social insurance * Signed consent for the study enrollment * Age ≥ 18 years Exclusion Criteria : * Patients in the group with metabolic fatty liver with hepatocellular carcinoma * Alcohol consumption ≤ 30 g/d (or 210 g/week) in men and ≤ 20 g/d (or 140 g/week) in women. * Decision (less than 3 months) to perform a liver biopsy of a tumor suspect of HCC and of adjacent liver in routine practice. * No systemic HCC treatment in the previous 6 months Group 2 Inclusion Criteria : * Available social insurance * Signed consent for the study enrollment * Age ≥ 18 years Exclusion Criteria : * Patients in the group with metabolic fatty liver without hepatocellular carcinoma * Alcohol consumption ≤ 30 g/d (or 210 g/week) in men and ≤ 20 g/d (or 140 g/week) in women. * Decision (less than 3 months) to perform a liver biopsy in routine practice. Liver biopsy will be organized because of one or more liver abnormalities and/or fatty liver seen at liver ultrasound due to the current lack of validated non-invasive marker of inflammation, cellular death and fibrosis in these patients. Group 3 Inclusion Criteria : * Available social insurance * Signed consent for the study enrollment * Age ≥ 18 years Exclusion Criteria : * Patients with an alcoholic liver disease with hepatocellular carcinoma * Alcohol consumption \> 30 g/d (or 210 g/week) in men and \> 20 g/d (or 140 g/week) in women. * Decision (less than 3 months) to perform a liver biopsy of a tumor suspect of HCC and of adjacent liver in routine practice. * No systemic HCC treatment in the previous 6 months Group 4 Inclusion Criteria : * Available social insurance * Signed consent for the study enrollment * Age ≥ 18 years Exclusion Criteria : * Patients with an alcoholic liver disease without hepatocellular carcinoma * Alcohol consumption \> 30 g/d (or 210 g/week) in men and \> 20 g/d (or 140 g/week) in women. * Decision (less than 3 months) to perform a liver biopsy in routine practice. No systemic HCC treatment in the previous 6 months. Liver biopsy will be organized because of one or more liver abnormalities and/or fatty liver seen at liver ultrasound due to the current lack of validated non-invasive marker of inflammation, cellular death and fibrosis in these patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcoholic liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de Nice

    Nice, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.